Effects of Survivin Antagonists on Growth of Established Tumors and B7-1 Immunogene Therapy
Authors:
- Wei-Ping ShenWSWei-Ping Shen
- Rupinder K. KanwarRKRupinder K. Kanwar
- Randal W. BergRBRandal W. Berg
- Geoffrey W. KrissansenGKGeoffrey W. Krissansen
Open Access
- 17 October 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 93 (20) , 1541-1552
Abstract
Background: Survivin, a member of the inhibitor of apoptosis (IAP) protein family, is detectable in most types of cancer, and its presence is associated with a poor prognosis. We determined the effects of gene-based therapies that inhibit survivin function in a mouse tumor model. Methods: Using five to six mice per treatment group, we injected tumors derived from mouse EL-4 thymic lymphoma cells with plasmids encoding antisense survivin, a dominant-negative mutant survivin, and the T-cell costimulator B7-1. Expression of endogenous survivin and the proteins encoded by the injected plasmids were examined by immunohistochemical staining of tumor sections and by western blot and flow cytometry analyses of isolated tumor cells. Tumor growth, the generation of antitumor cytotoxic T-lymphocyte (CTL) activity, apoptosis, and the contribution of leukocyte subsets to antitumor activity were measured. All statistical tests were two-sided. Results: Large (1.0-cm diameter) tumors had approximately 10-fold more survivin than small (0.2-cm diameter) tumors. At 28 days after injection, antisense and dominant-negative mutant survivin plasmids statistically significantly inhibited the growth of both small (P = .006 and P = .0018, respectively) and large (P<.001 for both plasmids) EL-4 tumors compared with tumors injected with empty plasmid. The growth of large tumors was further inhibited by intratumoral injection with antisense survivin and B7-1 (P = .004); thus, inhibition of survivin expression renders large tumors susceptible to B7-1-mediated immunotherapy. Mice whose tumors were completely eradicated by injection of B7-1 remained tumor free for 26 days after re-injection with EL-4 cells (when the experiment ended). Compared with tumors injected with empty plasmid, tumors injected with survivin-based plasmids had increased apoptosis, and animals bearing such tumors generated more antitumor CTLs. Conclusion: Intratumoral injection of plasmids that block survivin expression and stimulate the generation of tumor-specific CTLs may be beneficial for the treatment of large lymphomas.Keywords
This publication has 49 references indexed in Scilit:
- BIRinging Chromosomes through Cell Division—And Survivin' the ExperienceCell, 2000
- Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangementNature Structural & Molecular Biology, 2000
- Crystal Structure of Human Survivin Reveals a Bow Tie?Shaped Dimer with Two Unusual ?-Helical ExtensionsMolecular Cell, 2000
- Crystal Structure and Mutagenic Analysis of the Inhibitor-of-Apoptosis Protein SurvivinMolecular Cell, 2000
- Expression of the antiapoptosis gene, Survivin, predicts death from recurrent colorectal carcinomaGut, 2000
- Expression of the Novel Inhibitor of Apoptosis Survivin in Normal and Neoplastic SkinJournal of Investigative Dermatology, 1999
- Escaping Cell Death: Survival Proteins in CancerExperimental Cell Research, 1999
- The inhibitors of apoptosis (IAPs) and their emerging role in cancerOncogene, 1998
- Apoptosis by Death FactorCell, 1997
- Bcl-2 and the regulation of programmed cell deathJournal of Cell Biology, 1994